| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CGAS |
| Uniprot No | Q8N884 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 161-522aa |
| 氨基酸序列 | GASKLRAVLE KLKLSRDDIS TAAGMVKGVV DHLLLRLKCD SAFRGVGLLN TGSYYEHVKI SAPNEFDVMF KLEVPRIQLE EYSNTRAYYF VKFKRNPKEN PLSQFLEGEI LSASKMLSKF RKIIKEEIND IKDTDVIMKR KRGGSPAVTL LISEKISVDI TLALESKSSW PASTQEGLRI QNWLSAKVRK QLRLKPFYLV PKHAKEGNGF QEETWRLSFS HIEKEILNNH GKSKTCCENK EEKCCRKDCL KLMKYLLEQL KERFKDKKHL DKFSSYHVKT AFFHVCTQNP QDSQWDRKDL GLCFDNCVTY FLQCLRTEKL ENYFIPEFNL FSSNLIDKRS KEFLTKQIEY ERNNEFPVFD EF |
| 预测分子量 | 58 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于cGAS重组蛋白的3篇模拟参考文献及其摘要概括：
1. **《重组cGAS蛋白的高效表达与功能验证》**
作者：李明等
摘要：本研究通过大肠杆菌表达系统成功获得高纯度人源cGAS重组蛋白，优化表达条件后产量显著提升。通过体外酶活实验证实其可催化生成第二信使cGAMP，并激活STING通路下游干扰素表达，为后续药物筛选提供基础工具。
2. **《cGAS重组蛋白的晶体结构解析与DNA结合机制研究》**
作者：王晓东、张华
摘要：利用X射线晶体学技术解析了重组cGAS蛋白与双链DNA复合物的三维结构，揭示了其通过正电荷表面结合DNA的关键氨基酸残基，为理解cGAS激活机制及设计特异性抑制剂奠定结构基础。
3. **《重组cGAS在抗肿瘤免疫治疗中的潜在应用》**
作者：陈志坚课题组
摘要：通过体外实验证明，重组cGAS蛋白与纳米载体结合后可靶向递送至肿瘤细胞，增强胞内DNA感知能力，显著提升免疫检查点抑制剂的疗效，为肿瘤免疫联合治疗提供了新策略。
(注：以上文献为示例性内容，实际研究中请根据具体需求检索真实数据库如PubMed。)
**Background of cGAS Recombinant Protein**
The cyclic GMP-AMP synthase (cGAS) is a critical cytosolic DNA sensor in the innate immune system, first identified in 2013 as a pivotal component of mammalian antiviral defense. It detects aberrant cytoplasmic DNA, a hallmark of viral infections, mitochondrial stress, or genomic instability, and initiates a signaling cascade by synthesizing the second messenger 2',3'-cGAMP. This molecule binds to the stimulator of interferon genes (STING), triggering downstream production of type I interferons (IFNs) and proinflammatory cytokines. cGAS's role extends beyond pathogen detection; it is implicated in autoimmune diseases, cancer immunity, and cellular senescence, making it a focal point in immunology and therapeutic research.
Recombinant cGAS protein, produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), retains enzymatic activity and structural integrity for *in vitro* studies. Its recombinant form enables detailed biochemical characterization, including DNA-binding kinetics, enzymatic activity assays, and structural analyses (e.g., X-ray crystallography). Researchers leverage recombinant cGAS to explore mechanisms of DNA sensing, screen inhibitors for autoimmune conditions, or develop agonists to enhance antitumor immunity. However, challenges persist, such as optimizing protein solubility and minimizing aggregation due to its intrinsically disordered regions.
Recent advances highlight cGAS's dual roles: while chronic activation drives pathologies like lupus, its suppression may impair tumor surveillance. Thus, recombinant cGAS tools are vital for dissecting context-dependent regulation and designing targeted therapies. Ongoing studies aim to refine its activity modulation, balancing therapeutic efficacy with safety—a cornerstone for next-generation immunotherapies.
×
